logo
Plus   Neg
Share
Email

Britvic Q1 Revenue Up 4.8%; Reaffirms 2016 EBITA Guidance

Britvic plc. (BVIC.L) reported that revenue for the first-quarter was 311.6 million pounds, 4.8% ahead of last year. On an organic basis reported revenue declined 2.4% to 290.1 million pounds.

Simon Litherland, Chief Executive, said, "As anticipated, our first quarter performance reflected both the prevailing challenging trading conditions and a slow start in October. However trading over the entire Christmas period in our core markets was encouraging, with revenue ahead of last year, and in the quarter, we grew or held market value share in each of these markets."

With strong marketing and innovation plans for the year ahead, and an ongoing focus on cost control, the company reaffirmed its EBITA guidance range of 180 million pounds to 190 million pounds for 2016.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT